Introduction
Arachidonic acid (AA; 20:4, n-6) is a relatively minor polyunsaturated fatty acid found at the sn-2 position of cell membrane glycerolipids (1) . In contrast to other more abundant unsaturated fatty acids (i.e. oleic, linoleic or linolenic acid), levels of unesterified AA are stringently controlled within mammalian cells (2) . Pathways of AA uptake, incorporation and remodeling in glycerolipids are well documented (2) . Two distinct pathways, one that controls exposure of cells to low concentrations of AA and another that controls exposure to high AA concentrations, have been identified. The first is a 'high-affinity-low-capacity' pathway that incorporates low concentrations of intracellular AA into glycerolipids; this is thought to be the major pathway responsible for phospholipidarachidonate remodeling. Then there is a 'low-affinity-highcapacity' pathway that incorporates unesterified AA primarily into triglycerides (often seen in lipid bodies) and diarachidonyl phospholipids. This pathway functions primarily when the high-affinity pathway has been saturated when cells are exposed to high AA concentrations (2) (Figure 1 ). AA is also released from membrane glycerolipids, and once released, AA and its metabolites are important signals that regulate a wide range of cellular functions (3) (4) (5) .
Over the past decade, it has become apparent that AA metabolism plays a key role in carcinogenesis. Such data are particularly compelling with regard to cyclooxygenase (COX) mediated AA metabolism (6) . For example, the role of COX overexpression (7) (8) (9) (10) (11) (12) and COX-derived eicosanoids (13) (14) (15) (16) in carcinogenesis as well as the antineoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) (17) (18) (19) (20) are now firmly established. Similar lines of evidence have implicated the overexpression of other AA metabolic enzymes in cancer cell survival (21, 22) and have demonstrated the antineoplastic properties of inhibitors of these enzymes (23) (24) (25) .
The capacity of inhibitors of enzymes that metabolize AA to induce cancer cell apoptosis is of therapeutic interest, and the mechanism by which these inhibitors induce apoptosis is still a matter of debate. With regard to NSAIDs, the most well studied of these inhibitors, it is unclear whether their anti-neoplastic effects result from COX inhibition or COXindependent targets. For example, NSAIDs have been shown to effect putative targets such as PDK1, NAG-1, Wnt, Akt and others (reviewed in ref. 26) .
One hypothesis that is consistent with much of the data in the literature is that certain inhibitors of AA metabolism induce the intracellular accumulation of unesterified AA, which provides signals for cells to undergo apoptosis (4, 24, 27) (Figure 1 ). This notion is supported by studies that show that inhibition of COX, AA-CoA synthetase [also known as fatty acid CoA ligase 4 (FACL-4)] ( Figure 1 ) (2) and CoA-independent transacylase (CoA-IT) ( Figure 1 ) (2) induce the accumulation of unesterified AA in cancer cells at concentrations that lead to apoptosis (24, 27, 28) . Moreover, addition of exogenous AA to cancer cell lines leads to growth inhibition and apoptosis. Furthermore, the overexpression of enzymes such as COX, LOX (21, 29) and FACL-4 (22) , all of which lower intracellular AA levels, provides an apoptotic escape mechanism in several neoplastic cell types. Interestingly, Dong et al. (30) in human colon tumors. This phenotype would be predicted to maintain very low levels of intracellular AA and they hypothesize that establishment of this phenotype is a key step in early carcinogenesis. Finally, we have recently demonstrated that NS-398, PLT 98625 and triacsin C (inhibitors of COX, CoA-IT and FACL-4, respectively) induce accumulation of high levels of unesterified AA and apoptosis, and, in combination, act synergistically to produce both AA accumulation and apoptosis (31) .
However, a key question remains as to how accumulation of intracellular AA initiates apoptosis. The range of biological processes in which AA and its metabolites participate is vast, and thus an extensive number of possibilities exist. In this study we investigate changes in the gene expression induced by the accumulation of intracellular unesterified AA. AA and its metabolites have been shown to regulate the transcription of several families of genes including heat shock proteins (32, 33) , genes involved with cell cycle control (34), inflammation (35, 36) , steroid biosynthesis (37) and proto-oncogenes (38) (39) (40) . The current study demonstrates that AA-induced apoptosis is transcriptionally dependent and involves the regulation of key families of genes involved in cell survival and apoptosis.
Materials and methods

Materials
All cell culture reagents were purchased from Invitrogen (San Diego, CA). HCT-116 cell lines were maintained in McCoy's medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), L-glutamine and 100 U/ml penicillin-streptomycin. Triacsin C and sulindac sulfide were purchased from Biomol Research Laboratories (Plymouth Meeting, PA). PLT 98625 (formerly SK&F 98625) has been described previously (41) and was provided by Pilot Therapeutics (Winston-Salem, NC). Fatty acids were purchased from Cayman Chemical (Ann Arbor, MI). Etoposide, actinomycin D (ActD), 5,6-dichloro-1-b-Dribofuranosylbenzimidazole (DRB) and albumin were purchased from Sigma Chemical (St Louis, MO). [ 3 H]AA (200 mCi/nmol) was purchased from American Radiolabeled Chemical (St Louis, MO). Rabbit immunoaffinity-purified antibody to phospho-Jun was purchased from Upstate (Lake Placid, NY). Rabbit anti-Jun IgG was purchased from Cell Signaling Technology (Beverly, MA). Goat anti-rabbit IgG and anti beta-actin antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA).
MTS cell proliferation assay
Cell proliferation was quantified using the CellTiter 96 Aqueous MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)] colorimetric assay kit (Promega, Madison, WI). Cells were plated in appropriate medium at 10 000 cells/well in 96-well tissue culture plates and incubated at 37 C for 24 h. For experiments utilizing the transcriptional inhibitors DRB (50 mM) or ActD (1 mg/ml), cells were pre-treated with these inhibitors for 1 h. The appropriate treatments or vehicle were then added to each well and cells were incubated for an additional 48 h. The assay was then developed according to manufacturer's instructions and absorbance at 490 nm was measured.
Labeling of glycerolipids with [
3 H] AA to isotopic equilibrium and analysis of labeled products Cellular glycerolipids were labeled to isotopic equilibrium as described previously (28 In contrast to other abundant unsaturated fatty acids, levels of unesterified AA are tightly controlled by two distinct pathways working in coordination. The first pathway is referred to as 'high-affinity-low-capacity' because it incorporates low concentrations of intracellular AA into glycerolipids. This is the predominant pathway utilized. When the burden of unesterified AA overwhelms the low-capacity pathway, the cell increases incorporation of unesterified AA into neutral lipids via de novo glycerolipid biosynthesis utilizing a 'low-affinity-high-capacity' pathway. FACL-4 catalyzes an ester bond between AA and coenzyme A, which is the first reaction in both pathways. CoA-IT orchestrates the remodeling of AA between phospholipid pools such as phosphatidylcholine and phosphatidylethanolamine in a CoA-independent manner (2). Thus, PLT 98625, via inhibition of CoA-IT, impedes only the 'high-affinity-low-capacity', whereas triacsin C, via inhibition of FACL-4, inhibits both pathways.
Arachidonic acid-induced gene expression 48 h to allow [ 3 H] AA to reach constant label to mass ratios within all intracellular glycerolipid AA pools. Cells were then treated with triacsin C, PLT 98625, etoposide or vehicle for 18 h at 37 C. Intra-and extracellular lipids were extracted by the method of Bligh and Dyer (42) . Extracted lipids were combined with cold glycerolipid standards, spotted on silica gel G TLC plates (Analtech, Newark, DE) and developed using hexane : ethyl ether : formic acid (90 : 60 : 6 v/v). TLC zones were collected and analyzed by liquid scintillation spectroscopy to determine the amount of radioactive AA in each lipid pool.
RNA isolation
HCT-116 cells were seeded at 2 · 10 6 cells/dish in a 100 mm culture dish and incubated for 24 h. Cells were then treated with triacsin C (20 mM), AA (200 mM), sulindac sulfide (160 mM) or vehicle alone for 6 or 12 h, and total cellular RNA was isolated using TriZol reagent (Gibco, Grand Island, NY) following the manufacturer's instructions. For gene chip expression analysis each sample consisted of two pooled plates. Gene chip expression analysis RNA isolation, preparation and hybridization to the Human Genome U133A Array (Affymetrix, Santa Clara, CA) were performed according to the manufacturer's instructions. Isolated total cellular RNA was purified using an RNeasy Mini Kit (QIAGEN, Valencia, CA). Isolated and purified RNA (10 mg) was reverse-transcribed to cDNA using a Superscript II RT cDNA Synthesis Kit (Invitrogen, Carlsbad, CA) and T7 Oligo(dT) gene chip primers (Affymetrix). Biotin-labeled anti-sense cRNA was then synthesized using a BioArray HighYield RNA Transcript Labeling Kit (ENZO Biochem, New York, NY). Biotin-labeled cRNA was then purified and fragmented using the Gene Chip Sample Cleanup Module (Affymetrix) according to manufacturer's instructions. The fragmented labeled cRNA was hybridized to the Human Genome U133A Array (Affymetrix), which contains 22 215 human gene cDNA probes. After washing and staining, the arrays were scanned using an Agilent GeneArray Scanner (Germantown, MD). The gene expression levels of samples were normalized to internal standards and analyzed using Microarray Suite v5, MicroDB v3 and Data Mining Tool software v3 (Affymetrix). The difference of 22 215 gene expressions between samples from cells treated with AA or triacsin C were compared with samples from cells treated with vehicle alone.
Western blot analysis HCT-116 cells were seeded in 100 mm culture dishes at 2 · 10 6 cells/dish. After 24 h, cells were treated with AA, triacsin C or vehicle alone and incubated for an additional 12 h. Adherent and floating cells were harvested and total protein was isolated in NP40 lysis buffer, and 50 mg of total protein was separated by gel electrophoresis in 10-20% SDS-polyacrylamide precast gels (Bio-Rad) and transferred to polyvinylidene diflouride membranes (Bio-Rad). After blotting, bands were visualized using ECL-Plus (Amersham Pharmacia Biotech, UK).
Caspase activity assay Caspase activity was quantified using the Apo-ONE Homogenous Caspase Assay Kit (Promega). Cells were plated in a 96-well culture dish at 5000 cells/well in 100 ml of medium and incubated for 24 h at 37 C. Cells were then pre-incubated for 1 h with vehicle alone, DRB (50 mM) or ActD (1 mg/ml) and then treated with AA, triacsin C or vehicle alone and incubated for an additional 36 h. Floating and attached cells were then harvested and caspase activity was assayed according to the manufacturer's instructions.
Immunocytochemistry HCT-116 cells (2 · 10 5 ) were seeded in 35-mm-diameter cell culture dishes. Cells were incubated for 24 h and then pre-treated with vehicle alone, DRB (50 mM) or ActD (1 mg/ml). After 1 h, cells were then treated with vehicle alone, AA or triacsin C for an additional 36 h. Floating cells from the treated dishes were then harvested using cytospin, fixed in 3.7% formaldehyde for 15 min and permeabilized using 0.1% Triton X-100 in phosphate-buffered saline (PBS) for 5 min. After blocking in 1% bovine serum albumin (BSA) in PBS for 10 min, the cytospins were incubated with rabbit anti-cleaved PARP [poly(ADP-ribose)polymerase] antibody in 1% BSA for 30 min. The cytospins were then washed with PBS and incubated with 25 mg/ml goat anti-rabbit IgG conjugated with rhodamine for 30 min. After washing with PBS and formaldehyde post-fixation, the cytospins were stained with DAPI in methanol and mounted under a coverslip in glycerol. Images were prepared using a Zeiss Axioplan 2 microscope equipped with phase-contrast optics and UV excitation filters.
Results
Inhibitors of AA metabolism decrease cell viability and increase unesterified AA It has been previously reported that inhibition of AA uptake and remodeling enzymes, FACL-4 and CoA-IT, respectively, reduces the proliferation of certain cancer cell lines (24,44). We recently demonstrated that, in the SK-MES-1 non-small cell lung cancer cell line, AA remodeling inhibitors, COX inhibitors and exogenous AA induce apoptosis, which is dependent upon the intracellular accumulation of unesterified AA (31) . Others have demonstrated similar results in a variety of cell lines (4, 24, 27) . In the colon cancer cell line, HCT-116, inhibitors of AA remodeling enzymes also induced AA accumulation and decreased cell survival (Figure 2) . Specifically, inhibition of the 'high-affinity-low-capacity' pathway of AA remodeling by the CoA-IT inhibitor PLT 98625, or inhibition of both the 'high-affinity-low-capacity' and the 'lowaffinity-high-capacity' by the FACL-4 inhibitor, triacsin C, significantly reduces the viability of HCT-116 cells (Figure 2A ). Further studies were pursued with triacsin C, as it inhibits both pathways of AA remodeling. This reduction of cell viability in HCT-116 cells was associated with activation of caspase-3 activity (Figure 3 ).
Both the CoA-IT and FACL-4 inhibitors also induced the accumulation of unesterified AA. Within 18 h, 32 and 24% of the cell's total AA were released as free fatty acid into the medium in response to PLT 98625 (40 mM) and triacsin C (20 mM), respectively ( Figure 2B ). This effect was not due to cytotoxicity alone, as etoposide, a reagent that does not affect AA metabolism, reduced cell viability but failed to induce AA accumulation ( Figure 2 ). Addition of 200 mM exogenous AA also reduced HCT-116 cell viability (Figure 2A ). This effect is not observed with other control fatty acids (24,27).
AA-induced apoptosis is transcriptionally dependent
Although there is a growing body of evidence supporting the concept that apoptosis induced by inhibitors of AA metabolism is mediated by the accumulation of intracellular AA, little is known about the downstream pathways by which unesterified AA signals apoptosis. To test the hypothesis that AA induces apoptosis in a transcriptionally dependent manner, transcriptional inhibitors DRB and ActD were added to HCT-116 along with inhibitors of AA metabolism, and caspase-3 activity was measured (Figure 3 ). Both DRB and ActD were able to reverse caspase-3 activation induced by exogenous AA or triacsin C in HCT-116 cells (Figure 3 ), suggesting that transcription is required for apoptosis induced
by AA or FACL-4 inhibition. This result was confirmed using immunocytochemistry, which demonstrated that PARP cleavage, nuclear condensation and morphological changes of apoptosis in cells treated with AA and triacsin C are diminished by pre-treatment with ActD ( Figure 4) . Transcriptional inhibition was, however, unable to improve the viability of HCT-116 cells, as these transcriptional inhibitors are cytotoxic after 48 h ( Figure 5 ). On the basis of these experiments it was postulated that transcriptional regulation of genes involved in cell survival and apoptosis were downstream mechanisms by which AA accumulation signals apoptosis.
AA accumulation influences gene expression
To further investigate whether specific genes may play a role in AA-induced apoptosis, gene chip technology was employed. HCT-116 cells were incubated with triacsin C or exogenous AA for 6 or 12 h and then total cellular RNA was extracted, transformed to biotinylated cRNA and hybridized to Affymetrix Human Genome U133A array, which contains 22 215 human gene cDNA probes. A 6 h time point was chosen to examine early changes in gene expression, as unesterified AA accumulation in the extracellular media is seen as early as 6 h and presumably the intracellular accumulation occurs even earlier. A 12 h time point was also chosen to examine genes whose expression may change later, but still before the morphological changes associated with apoptosis. At 6 h, 769 and 437 targets were upregulated 2-fold by AA and triacsin C, respectively ( Figure 6A ). Two hundred and nineteen of these were commonly upregulated by both AA and triacsin C. At 12 h, 832 and 189 targets were upregulated 2-fold by AA and triacsin C, respectively ( Figure 6A ). Of these, 107 were commonly upregulated by both AA and triacsin C ( Figure 6A ). Of the 22 215 targets, 29 (0.13%) were upregulated by both triacsin C and AA at both the 6 and 12 h time points ( Figure 6A , Table I ). The large overlap of upregulated genes by triacsin C-and AA-treated cells suggested a common mechanism of transcriptional regulation in the two treatments.
Similarly, genes whose expression was downregulated by >2-fold were examined at 6 and 12 h ( Figure 6B ). Downregulation of expression was minimal at 6 h. At 12 h, 40 of 22 125 targets (0.18%) were downregulated 2-fold by both AA and triacsin C (Table II) .
Activator protein-1(AP-1) transcription factors are primary target genes affected by AA accumulation Interestingly, the majority of upregulated targets function in signal transduction or as transcription factors and are implicated in apoptosis and cell cycle progression (Table I) . Of the 29 common upregulated targets, at both 6 and 12 h, 6 code for AP-1 proteins implicated in Jun dimerization and apoptotic signaling and 2 more code for the early growth response protein 1 (EGR-1) zinc finger transcription factor, which has been shown to physically interact with c-Jun in neuronal apoptosis (45, 46) (Table I) . Together, these data suggested that Arachidonic acid-induced gene expression perturbations of cellular AA levels may signal apoptosis through the AP-1 transcription factors. To confirm these results, mRNA and protein levels of one of these AP-1 transcription factors, c-Jun, which was upregulated on the gene array, was measured by real-time PCR and protein immunoblotting ( Figure 7) . As predicted by gene array experiments, c-Jun was upregulated in response to both triacsin C and AA at both the transcript and protein levels. Furthermore, triacsin C and AA also induce c-Jun phosphorylation (Figure 7) , which is an important regulatory step in its transcriptional activation. The COX-2 inhibitor, sulindac sulfide, is also known to reduce cell viability and induce intracellular unesterified AA accumulation in HCT-116 (27) . Real-time PCR demonstrated that incubation of HCT-116 with sulindac sulfide upregulates c-Jun expression levels 6.82-fold (P < 0.001).
Discussion
Tumor cell carcinogenesis is often accompanied by dramatic changes in the levels of key enzymes that take up, remodel, release and metabolize AA. This observation taken together with the fact that inhibitors of AA metabolism can markedly affect the viability of a number of cancer cells implicate that AA metabolism may play a pivotal role in the survival of certain cancers. Our laboratory has previously shown that inhibitors of AA uptake, remodeling and metabolism induce apoptosis in SK-MES-1 cells and that this apoptosis is probably mediated by the accumulation of unesterified AA (31) . Other studies have also drawn similar conclusions with regard to COX inhibition (27) , FACL-4 inhibition (22) and CoA-IT inhibition (28) . 
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Nowhere have these observations been more dramatic than in models of colon cancer. In fact, the original observations of the chemopreventive effects of COX inhibition were made in colon cancer incidence (47) . Colon cancer cells appear to have developed elegant strategies to control levels of AA and AA metabolites produced within the cell. For example, it has been recognized for sometime that elevation of COX-2 expression and prostaglandin-E2 (PGE 2 ) production is often associated As measured using gene chip technology. The average fold change is the increase in expression for the given gene target in response to both treatments and at both time points versus cells treated with vehicle alone. Potential implications in cancer pathogenesis were determined by a literature review.
Arachidonic acid-induced gene expression with cancer cell survival. Moreover, a high COX-2/low cPLA 2 phenotype has recently been described and suggested to play a key role in early colon carcinogenesis (30) . Such a phenotype would maintain very low levels of intracellular AA, as little would be generated by cPLA 2 and that which was generated would be rapidly metabolized by the high levels of Cox-2. This is a characteristic that would be predicted to protect cell survival by preventing apoptosis secondary to intracellular AA accumulation.
As expected, the current study revealed that inhibition of AA metabolism reduces cell viability and induces accumulation of unesterified AA in the colon cancer cell line, HCT-116. Accumulation of unesterified AA was not simply an artifact of cell death, as etoposide, which does induce cell death, did not increase AA levels. Furthermore, AA accumulation was seen as early as 6 h post-treatment, whereas the morphological changes of apoptosis were not observed until 24 h posttreatment (data not shown).
If the accumulation of unesterified AA mediates this cytotoxicity, then treatment of cells with unesterified AA, at concentrations high enough to overcome its incorporation into cellular sinks, should also be cytotoxic. As predicted, exogenous unesterified AA (200 mM) was also cytotoxic to HCT-116 cells. Human serum AA concentrations are normally in the 300-400 mM range (48) and can be significantly elevated in specific human diseases. However, the vast majority of AA in serum exists esterified to the glycerol backbone of phospholipids and triglycerides, and normal physiological concentrations of unesterified AA are probably well <200 mM. The necessity of supra physiological concentrations of unesterified AA to induce cytotoxicity is to be expected, as these concentrations would be required to overwhelm the coenzyme As measured using gene chip technology. Average fold change is the decrease in expression for the given gene target in response to both treatments and at both time points versus cells treated with vehicle alone. Potential implications in cancer pathogenesis were determined by a literature review.
A-dependent and coenzyme A-independent enzymatic steps that incorporate AA into cellular glycerolipids. The response to exogenous AA does not appear to be a detergent effect, as other unsaturated fatty acids do not induce this same response. Furthermore, it is likely that detergent effects would induce necrosis rather than apoptosis. These results, coupled with similar findings in numerous other studies (3, 24, 27, 28, 49) , indicate that the response of HCT-116 cells to AA metabolic inhibitors is probably mediated by an increase in unesterified AA. Deciphering a common downstream pathway of apoptotic signaling by perturbations in AA metabolism is a critical next step in understanding the role of AA metabolism in carcinogenesis. Initial experiments in this study have showed that cytotoxicity induced by AA accumulation is caspase-3-and gene transcription-dependent. A transcriptionally dependent apoptotic process coupled with the knowledge that AA and its metabolites have been shown to alter the transcription of certain genes in other cell types (50) led us to further examine the role of transcriptional regulation in apoptosis induced by AA and triacsin C.
Interestingly, a large proportion of genes affected by AA and triacsin C are involved in apoptosis and growth inhibition and have known implications in carcinogenesis (Table I) . A number of the upregulated genes alter Erk/MAP kinase signaling by ras family members, which is one of the most well-defined and widely implicated pathways in carcinogenesis. 14-3-3 zeta is a member of 14-3-3 family signal transduction proteins known to interact with ras and raf in regulation of cell cycle progression and apoptotic induction (51) . RAPGEF2 is a rap guanine nucleotide exchange factor known to activate rap (52) , which functions to counteract ras signaling pathways (53) . ARHGDIA is a Rho-GDP disassociation inhibitor known to inactivate Rho signaling pathways (54) that function in cell proliferation (55) . Additionally, SQSTM1 (P62) is a negative regulator of Ras signaling pathways (56) .
Of the 29 upregulated targets identified by the selection strategy outlined in Figure 6A , 6 code for transcription factor AP-1 proteins implicated in Jun dimerization and apoptotic signaling and 2 more code for the EGR-1 zinc finger transcription factor, which has been shown to physically interact with c-Jun in apoptotic signaling (45, 46) (Table I) . AP-1 was among the first mammalian transcription factors identified (57) and regulates a broad spectrum of processes including cell proliferation, death, survival and differentiation (58) . In Arachidonic acid-induced gene expression fact, many members of the AP-1 family are proto-oncogenes. Structurally, the AP-1 transcription factor consists of a dimer of two basic region-leucine zipper proteins of the AP-1 family. Members of this family include the Jun subfamily (c-Jun, JunB, JunD), the Fos subfamily (c-Fos, FosB, Fra-1, Fra-2), the Maf subfamily (c-Maf, MafB, MafA, MafG/F/K) and the ATF subfamily (ATF-2, ATF-3, B-ATF, JDP1, JDP2) (58) .
Other studies also demonstrated upregulation of AP-1 transcription factors by AA (40, 59) . Together, these data suggest that intracellular burdens of unesterified AA may signal apoptosis through the AP-1 transcription factors. The role of c-Jun expression was further examined and it was demonstrated that perturbations in AA lead to both elevated transcript and protein levels. AA and triacsin C also caused phosphorylation of c-Jun, a known marker of activation. Future studies are under way in our laboratory to further investigate these results and their mechanistic significance. Given the prominent role COX inhibitors have played in colon cancer prevention, the effects of a COX inhibitor, sulindac sulfide, was also examined. Sulindac sulfide induced the upregulation of c-Jun expression at concentrations that induce marked AA accumulation and apoptosis. It is possible that these effects of sulindac are COX-independent, as it is unclear whether HCT-116 cells express COX-2. HCT-116 cells do, however, produce low levels of PGE 2 and can be induced to produce higher levels (60) . Additionally, at concentrations used (160 mM) in the current study, sulindac sulfide inhibits both COX isoforms (61) .
When focusing on genes whose expression was downregulated, fewer genes were altered. However, the majority of these genes are also associated with cancer biology (Table II) . For example, a number of these genes act as growth factors (i.e. BDNF) (62-64), growth factor receptors (i.e. fibroblast growth factor receptor 3) (65-68), signal transduction molecules (i.e. P45) (69) and proteins involved in DNA and RNA metabolism (i.e. topoisomerase 2A) (70) , whose downregulation could disrupt the growth potential of malignant cells. Given the growing collection of data suggesting a chemoprotective effect of NSAIDs and the link between AA metabolism and carcinogenesis, it is essential to understand the mechanism(s) by which perturbing AA metabolism affects cancer cell growth. While large amounts of data have been generated by this array study, more detailed experiments focusing on specific gene families will be necessary to better determine the role of specific signaling pathways. However, given the broad array of genes and pathways that are altered, it is unlikely that a single pathway or gene will be responsible for induction of apoptosis by AA. Perhaps, more importantly, this study points out the potential for perturbations in cellular AA levels to have broad and coordinated effects on the growth of cancer cells. For almost four decades now, AA metabolism has been shown to play a crucial role in the biology of processes that range from inflammation to reproduction. Studies such as this one build on an ever-growing literature that suggests that AA metabolism is a promising target for cancer therapy.
